Galectin Therapeutics Inc (NASDAQ:GALT), a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the screening of the first …
Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that Marc Rubin, M.D.
Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that in an open-label Phase …
Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reported financial results for the three …
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the …
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces it has engaged the contract research …
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces details of the design of its …
In a research report published today, MLV analyst Vernon Bernardino reiterated a Buy rating on shares of Galectin Therapeutics (NASDAQ:GALT) with a $16 price target, following final …
MLV’s healthcare analyst Vernon Bernardino today weighed in with his thoughts on several stocks, which have promising candidates in clinical development for liver diseaes, following the news …
In a research report sent to investors today, MLV analyst Vernon Bernardino reiterated a Buy rating on Galectin Therapeutics (NASDAQ:GALT) with a price …
